Autolus Therapeutics plc (NASDAQ:AUTL) is one of the

7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Mizuho lowered its price target on Autolus Therapeutics plc (NASDAQ:AUTL) to $10 from $12 previously and maintained an Outperform rating on the company shares after updating its models across its small-cap biotech coverage following the fourth quarter earnings reports.

On March 27, 2026, Autolus Therapeutics plc (NASDAQ:AUTL) reported fourth quarter EPS of (34c), compared to the (43c) consensus estimate, with revenue of $24.29 million versus $23.29 million consensus. Chief Executive Officer Christian Itin said that Autolus Therapeutics plc (NASDAQ:AUTL) had a “strong first year of launch” for AUCATZYL in the U.S., highlighting the commercial execution, product delivery, and real-world data showing clinical activity with low rates of high-grade CRS and ICANS. Chief Executive Officer Christian Itin added that the positive customer experience should support the future growth of AUCATZYL.

Photo by National Cancer Institute on Unsplash

Autolus Therapeutics plc (NASDAQ:AUTL) develops T cell therapies for cancer and autoimmune diseases in the United Kingdom and internationally.

While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.